SCHEMBL16046811

SCHEMBL16046811

COc1nc(SC)ncc1-c1ccc(Oc2ccnc(Cl)c2)c(C)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 1/20 0.39
▸ CSF1R P07333 16/20 0.38
▸ FLT3 P36888 5/20 0.38
▸ PDGFRA P16234 8/20 0.37
▸ PDGFRB P09619 4/20 0.37
▸ KDR P35968 2/20 0.37
▸ LCK P06239 1/20 0.37
▸ KIT P10721 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ PTK6 Q13882 1/20 0.37
▸ GAA P10253 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ CCNT1 O60563 1/20 0.33
▸ CCNA2 P20248 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ CCNA1 P78396 1/20 0.33
▸ CDK5 Q00535 1/20 0.33
▸ CDK5R1 Q15078 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16076003 0.85 GAA (0.34) TGFBR1GAAHTTLMNA
SCHEMBL30673538 0.81 CSF1R (0.60) CSF1RFLT3PDGFRAPDGFRBKDR
SCHEMBL16049246 0.81 CSF1R (0.60) CSF1RFLT3PDGFRAPDGFRBKDR
SCHEMBL16048014 0.81 CSF1R (0.47) TGFBR1CSF1RFLT3PDGFRAPDGFRB
SCHEMBL16046316 0.81 CSF1R (0.47) TGFBR1CSF1RFLT3PDGFRAPDGFRB
SCHEMBL21824041 0.80 BCL6 (0.41) CSF1RFLT3PDGFRAPDGFRBKDR
SCHEMBL26944633 0.79 CSF1R (0.40) CSF1RFLT3PDGFRAPDGFRBKDR
SCHEMBL21824019 0.78 MDM2 (0.39) CSF1RFLT3PDGFRAPDGFRBKDR
SCHEMBL30673536 0.78 MDM2 (0.39) CSF1RFLT3PDGFRAPDGFRBKDR
SCHEMBL21824002 0.77 CSF1R (0.36) CSF1RFLT3PDGFRAPDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107311981-B 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activity 德西费拉制药有限责任公司 2020-05-29 — — CN disclosed
EP-2968286-B1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2017-09-13 — — EP disclosed
EP-2968286-A2 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, LLC (US) 2016-01-20 — — EP disclosed
US-9181223-B2 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-10 — — US disclosed
US-20140275085-A1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — US disclosed
WO-2014145025-A2 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275085-A1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES CSF1R, KIT, CSF3R TGFBR1 1569/4885CSF1R 1/4885FLT3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback